atai Life Sciences to Participate in September Investor Conferences

Rhea-AI Summary

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in three major investor conferences this September.

The company will participate in fireside chat sessions at the Cantor Global Healthcare Conference on September 5th, the H.C. Wainwright Global Investment Conference on September 8th, and the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17th. All presentations will be available via webcast on the company's investor relations website, with replays accessible after the events.

NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences.

Details of the Company’s participation are as follows:

Cantor Global Healthcare Conference 2025

Format: Fireside Chat
Date: Friday, September 5^th at 8:35 a.m. ET
Location: New York, NY

H.C. Wainwright 27^th Annual Global Investment Conference

Format: Fireside Chat
Date and Time: Monday, September 8^th at 11:30 a.m. ET
Location: New York, NY

TD Cowen 5^th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Format: Fireside Chat
Date and Time: Wednesday, September 17^th at 10:00 a.m. ET
Location: Virtual

The webcasts for the fireside chat will be available on atai’s website under Events on the Investors section of the atai website. Replays will be available following the live events.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.

Contact Information
Investor Contact:
IR@atai.com

Media Contact:
PR@atai.com

FAQ

When is atai Life Sciences (ATAI) presenting at the Cantor Global Healthcare Conference 2025?

atai Life Sciences will present at the Cantor Global Healthcare Conference on Friday, September 5th at 8:35 a.m. ET in New York, NY.

How can investors access atai Life Sciences' (ATAI) September 2025 conference presentations?

Investors can access the webcasts of the fireside chats through the Events section of atai's investor relations website. Replays will be available after the live events.

What type of company is atai Life Sciences (ATAI)?

atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing highly effective mental health treatments to transform patient outcomes.

Which investor conferences will atai Life Sciences (ATAI) attend in September 2025?

atai will participate in three conferences: the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), and TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Sept 17).